Concepedia

Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease

Lailiang Qu, Shang Li, Limei Ji, Si Luo, Ming Ding, Fucheng Yin, Cheng Wang, Heng Luo, Dehua Lu, Xingchen Liu,

European Journal of Medicinal Chemistry · 2021 · 45 citations · 44 references

DOIFull text

Open access

Concepts

References

44

HADDOCK:  A Protein−Protein Docking Approach Based on Biochemical or Biophysical Information

Cyril Dominguez, Rolf Boelens, Alexandre M. J. J. Bonvin · Journal of the American Chemical Society · 2003 · 3.2K citations · Full text

Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

Kathleen M. Sakamoto, Kyung B. Kim, Akiko Kumagai et al. · Proceedings of the National Academy of Sciences · 2001 · 2.3K citations · Full text

<scp>2021</scp> Alzheimer's disease facts and figures

Alzheimer s & Dementia · 2021 · 2.1K citations

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text